These studies provide proof‐of‐principle preclinical data supporting KLF4/MAP2K7/JNK/ATF2 pathway inhibition as a potential targeted therapy for T‐ALL [139, 140]. Here, KLF4 is linked to acute lymphoblastic leukemia.